KCNJ11
ATP-sensitive inward rectifier potassium channel 11
As of the edition of 20 October 2026, KCNJ11 (ATP-sensitive inward rectifier potassium channel 11, UniProt Q14654) has 14 drugs tested at it and 21 companies on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q14654
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 9
- Disease areas
- Nutrition and metabolism; Hormones; Heart and blood vessels; Nervous system; Urinary and reproductive; Pregnancy and women's health; Cancer; Digestive system
- Registered trials of its drugs
- 330
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 14 |
| Total | 14 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Glimepiride | Marketed | Phase 4 | none listed |
| Glyburide | Marketed | Phase 4 | none listed |
| Repaglinide | Marketed | Phase 4 | none listed |
| Diazoxide | Marketed | Phase 4 | none listed |
| Gliclazide | Marketed | Phase 4 | none listed |
| Tolbutamide | Marketed | Phase 1 | none listed |
| Glipizide | Marketed | Phase 4 | none listed |
| Nateglinide | Marketed | Phase 4 | none listed |
| Mitiglinide | Marketed | Phase 4 | none listed |
| Acetohexamide | Marketed | Phase 3 | none listed |
| Mitiglinide calcium dihydrate | Marketed | Phase 4 | none listed |
| Chlorpropamide | Marketed | No phase stated | none listed |
12 of 14 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Engaged | 3 |
| Undetermined | 17 |
| Total on the list | 21 |
| Company | Route |
|---|---|
| Novo Nordisk | Route B |
The other 20 companies at KCNJ11
In the product21 companies in all; 20 are not named here, and no score is.
See the 21 companies at KCNJ11, ranked, with the facts behind eachRequest access. Nothing is shown until you do.